Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women
NCT00440258Phase 3Completed
- Sponsor
- IVI
- Start
- Apr 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of cabergoline in ovarian hyperstimulation syndrome (OHSS), sponsored by IVI. Started Apr 2004; status: completed.
02
Drugs
cabergoline
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT00440258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00440258.